Heterologous immunity provides a potent barrier to transplantation tolerance.
10.1172/jci200317477 · 2003
Increased pretransplant frequency of CD28+ CD4+ TEM predicts belatacept-resistant rejection in human renal transplant recipients.
10.1111/ajt.14350 · 2017
Belatacept-resistant rejection is associated with CD28+ memory CD8 T cells.
10.1111/ajt.14349 · 2017
Memory T-cell exhaustion and tolerance in transplantation.
10.1111/imr.12824 · 2019
TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients.
10.1172/jci80445 · 2015
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.
10.1038/s41590-018-0132-0 · 2018
Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses.
10.1016/j.immuni.2014.02.012 · 2014
TIGIT predominantly regulates the immune response via regulatory T cells.
10.1172/jci81187 · 2015
Implication of TIGIT(+) human memory B cells in immune regulation.
10.1038/s41467-021-21413-y · 2021
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells.
10.1038/ni.1674 · 2009
Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity.
10.4049/jimmunol.1700407 · 2018
TIGIT limits immune pathology during viral infections.
10.1038/s41467-020-15025-1 · 2020
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer(☆).
10.1016/j.annonc.2021.11.002 · 2022
Tiragolumab (anti-TIGIT) in SCLC: Skyscraper-02, a towering inferno.
2023
Anti-TIGIT antibody tiragolumab alone or with atezolizumab in patients with advanced solid tumors: a phase 1a/1b nonrandomized controlled trial.
10.1001/jamaoncol.2023.3867 · 2023
Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
10.1007/s00280-023-04627-3 · 2024
TIGIT agonism alleviates costimulation blockade-resistant rejection in a regulatory T cell-dependent manner.
10.1016/j.ajt.2022.12.011 · 2023
Pathogen stimulation history impacts donor-specific CD8 T cell susceptibility to costimulation/integrin blockade-based therapy.
10.1111/ajt.13399 · 2015
Secondary memory CD8+ T cells are more protective but slower to acquire a central-memory phenotype.
10.1084/jem.20052237 · 2006
Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection.
10.1172/jci8082 · 1999
Blocking TIGIT/CD155 signalling reverses CD8(+) T cell exhaustion and enhances the antitumor activity in cervical cancer.
10.1186/s12967-022-03480-x · 2022
Increased expression of multiple co-inhibitory molecules on malaria-induced CD8(+) T cells are associated with increased function instead of exhaustion.
10.3389/fimmu.2022.878320 · 2022
Master regulator activating transcription factor 3 (ATF3) in metabolic homeostasis and cancer.
10.3389/fendo.2020.00556 · 2020
RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis.
10.1158/0008-5472.can-11-3055 · 2013
Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.
10.1111/ajt.16386 · 2021
CD57(+) CD4 T cells underlie belatacept-resistant allograft rejection.
10.1111/ajt.13613 · 2016
TIGIT regulates apoptosis of risky memory T cell subsets implicated in belatacept-resistant rejection.
10.1111/ajt.16571 · 2021
Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines.
10.1038/83144 · 2001
Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses.
10.1016/j.immuni.2022.02.005 · 2022
Anti-TIGIT therapies for solid tumors: a systematic review.
10.1016/j.esmoop.2023.101184 · 2023
